ClinConnect ClinConnect Logo
Search / Trial NCT00000669

A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of May 11, 2025

Completed

Keywords

Didanosine Drug Evaluation Acquired Immunodeficiency Syndrome Aids Related Complex

ClinConnect Summary

AMENDED: Based on safety established in the first dosing phase of 52 weeks and long term dosing data in adults, the dosing period will be extended to 104 weeks. Original design: Information presently available indicates that ddI has high antiviral activity with less apparent toxicity than zidovudine (AZT) (the drug presently used to treat AIDS).

AMENDED: Dosing will proceed for 104 weeks at each dose level. Original design: Five patients are treated at the initial dose level. Because ddI is not stable in the acid environment of the stomach, oral doses of ddI follow administration of an ant...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis if this drug is extended to children.
  • Acute therapy not exceeding 7 days with oral or intravenous acyclovir for herpes simplex infections.
  • Trimethoprim / sulfamethoxazole for Pneumocystis carinii infections during course of study at discretion of investigator after discussion with the sponsor.
  • Symptomatic therapy with analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy as deemed necessary by the principal investigator.
  • Patients must have:
  • Diagnosis of AIDS as defined by CDC or meeting CDC P2 classification.
  • Patients must be free of opportunistic infection or other serious bacterial, fungal, or parasitic infection at time of entry into study.
  • Life expectancy \> 6 months.
  • Parent or guardian (and patient as applicable) able to give informed consent.
  • Available for follow-up for at least 6 months.
  • Allowed: Hemophilia.
  • Exclusion Criteria
  • Co-existing Condition:
  • Children with the following are excluded:
  • Chronic hematologic disorders unrelated to coagulation defects, hemoglobinopathies, or ITP.
  • Intractable diarrhea.
  • No venous access.
  • History of seizures within previous 2 years or currently requiring anticonvulsants for control.
  • Currently active heart disease as evidenced by a cardiac arrhythmia or other significant abnormality on routine electrocardiography (ECG) or shortening fraction of \< 10 percent on echocardiogram.
  • Renal disease.
  • Any other clinical condition that in the opinion of the investigator makes the patient unsuitable for study.
  • Concurrent Medication:
  • Excluded:
  • Antiretroviral drugs.
  • Zidovudine (AZT).
  • AL 721.
  • Interferon.
  • Corticosteroids.
  • Immunomodulating drugs.
  • Other systemic investigation agent.
  • Ribavirin.
  • Rifampin, barbiturates, or any other potent inducer or inhibitor of drug-metabolizing enzymes.
  • Cytotoxic anticancer therapy.
  • H-2 blockers.
  • Intravenous ketoconazole.
  • Immunoglobulin preparations.
  • Children with the following are excluded:
  • Chronic hematologic disorders unrelated to coagulation defects, hemoglobinopathies, or ITP.
  • Intractable diarrhea.
  • No venous access.
  • History of seizures within previous 2 years or currently requiring anticonvulsants for control.
  • Currently active heart disease as evidenced by a cardiac arrhythmia or other significant abnormality on routine electrocardiography (ECG) or shortening fraction of \< 10 percent on echocardiogram.
  • Renal disease.
  • Any other clinical condition that in the opinion of the investigator makes the patient unsuitable for study.
  • Renal disease.
  • Prior Medication:
  • Excluded:
  • Any prior therapy which in the opinion of the investigator would make the patient unsuitable for study.
  • Excluded within 2 weeks of study entry:
  • Trimethoprim / sulfamethoxazole.
  • Excluded within 1 month of study entry:
  • Study drug or other antiretroviral drug or systemic investigational agent.
  • Any agent known as a potent inducer or inhibitor of drug metabolizing enzymes.
  • H-2 blockers.
  • Ketoconazole.
  • Immunoglobulin preparations.
  • Excluded within 3 months of study entry:
  • Ribavirin.
  • Excluded:
  • Zidovudine (AZT) for \> 6 months.
  • Cytotoxic anticancer therapy.
  • Prior Treatment:
  • Excluded within 4 weeks of study entry:
  • Blood transfusion.
  • Lymphocyte transfusions for immune reconstitution.
  • Bone marrow transplant.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Houston, Texas, United States

Birmingham, Alabama, United States

Houston, Texas, United States

Miami, Florida, United States

Memphis, Tennessee, United States

Patients applied

0 patients applied

Trial Officials

Scott GB

Study Chair

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials